Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD147-CART in Recurrent Glioblastoma
NCT04045847Phase 1Unknown
- Sponsor
- Xijing Hospital
- Start
- May 2019
- Primary completion
- Oct 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD147 CAR T-cells in glioblastoma (GBM), sponsored by Xijing Hospital. Primary endpoint: Incidence and type of adverse events induced by CD147-CART at 12 weeks. Status: unknown.
02
Drugs
CD147 CAR T-cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04045847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04045847.